The diagnosis and management of autoimmune pancreatitis (AIP) is challenging in certain patient groups. This retrospective study evaluated the diagnosis and management of AIP in 22 patients (95% male, mean age 64.8 y (range 43-84 y)) diagnosed at the Freeman Hospital, England, between 2005 and 2013. Type I (n=21) AIP was more common than type II AIP (n=1). Patients presented most frequently with abnormal liver function tests (LFTs) without jaundice (77%), weight loss (41%) and acute abdominal pain without hyperamylasemia (27%). Pancreatic exocrine insufficiency was identified in 41% and a further 23% of patients were diabetic at presentation. Total immunoglobulin IgG, IgG4 and Ca19-9 were elevated in 45%, 64% and 73% of patients respectively. Extrapancreatic involvement was prominent (68% of patients), most commonly bile duct strictures (64%), gall bladder and peripancreatic infiltration (9%) and retroperitoneal fibrosis (9%). All patients underwent a pancreatic protocol CT which most commonly identified pancreatic head enlargement (50%) and thickening/stricturing of the extrapancreatic (50%) and intrahepatic bile duct dilataion (45%). Corticosteroid therapy was initiated in 82% of patients. 23% relapsed and were treated with azathioprine. In all cases symptom alleviation was achieved following two weeks of treatment and Ca19-9 normalised. LFTs normalised in 12 patients by the fourth week of treatment. Four patients had sub-optimal response to immunosuppression with one death due to end stage liver failure. Overall the diagnosis and management of AIP is challenging and may be best achieved with a multi-disciplinary team. 
one death due to end stage liver failure. Overall the diagnosis and management of AIP is challenging and may be best achieved with a multi-disciplinary team. The lack of clear clinical criteria to discriminate malignant from benign cystic pancreatic lesions causes management uncertainty. This retrospective study of 125 patients with cystic lesions of the pancreas led to creation of a two-step diagnostic pathway using contrast-enhanced endoscopic ultrasound and endoscopic fine needle aspiration. Firstly, contrast-enhanced endoscopic ultrasound should be used to evaluate for signs of cystic neoplasia in the pancreas including cystic wall diameter >3cm, septae, nodules within the cyst, pancreatic duct dilatation and cystic wall vascularisation. If any of these features are identified, endoscopic fine-needle aspiration of the lesion with prophylactic antibiotics is indicated to evaluate malignant potential. Lesions with mucous liquid, carcinoembryonic antigen (CEA) level >400 or which meet cytological tumour criteria should be considered for surgical intervention. Follow-up is advised for patients with serous liquid, CEA <400 and cytological normal cells. Although clinically useful, it is important for future studies to evaluate the effectiveness of this proposed diagnostic pathway.
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Achieving an early histopathological diagnosis of pancreatic cancer is important to target treatment and reduce morbidity and mortality. This multi-centre prospective study of 197 consecutive patients (77% male) with pancreatic head masses from 2008 to 2013 compared the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) (n=72) with percutaneous ultrasoundguided fine needle aspiration (US-FNA) (n=125). A sensitivity of 84%, specificity of 100%, positive predictive value (PPV) of 100%, negative predictive value (NPV) of 73% and overall accuracy of 89% was demonstrated with EUS-FNA compared to a sensitivity of 86%, specificity of 90%, PPV of 95%, NPV of 76% and overall accuracy of 87% with US-FNA. A complication rate of 1.4% and 5.6% was observed with EUS-FNA and US-FNA respectively. Notably three patients who underwent US-FNA had procedure related tumour seeding. Endoscopic ultrasound allowed aspiration of smaller lesions compared with percutaneous ultrasound (9mm and 20mm respectively). Despite similar diagnostic accuracies the authors conclude EUS-FNA is preferable to US-FNA given the lower complication rate and smaller size of accessible lesions. Diagnostic accuracy may be enhanced by adopting a three pass approach and on-site cytopathology facilities. An evidence-based approach to the diagnosis, investigation and management of acute pancreatitis (AP) is provided by this American College of Gastroenterology guideline constructed following a MEDLINE search of clinical trials, reviews, guidelines and meta-analysis related to AP between 1966 and 2012. In general the diagnosis of AP requires two out of three features: congruent abdominal pain history, serum amylase/lipase greater than three times the upper limit of normal and characteristic imaging findings. A transabdominal ultrasound scan should be performed in all AP patients to investigate for gallstones. In the absence of gallstones or a significant alcohol history serum triglycerides should be measured. Cases of idiopathic AP should be referred to a specialist centre and genetic testing should be considered in young patients (<30 y) with unclear aetiology and a family history of pancreatic disease. The role of contrastenhanced CT and MRI is limited. In the absence of significant comorbidities early aggressive intravenous fluid resuscitation, preferably with lactate Ringer's solution, should be provided to prevent complications such as pancreatic necrosis. The presence of organ failure signifies moderatesevere AP and a need for management in an intermediary/intensive care unit. ERCP should be completed within 24 h of admission in patients with AP and acute cholangitis but early ERCP is not generally required in gallstone pancreatitis without ongoing biliary obstruction. ERCP with guidewire cannulation is preferable to radiocontrast since pancreatic hydrostatic injury is avoided. EUS or MRCP should be used to screen for choledocholithiasis if highly suspected in the absence of cholangitis and/or jaundice. Pancreatic duct stents and/or post procedure rectal NSAID suppositories should be used to lower the risk of severe post-ERCP pancreatitis in high-risk patients. The prevention and early treatment of infected pancreatic necrosis is important to reduce mortality however prophylaxis with antibiotics or anti-fungal agents is not recommended in cases of severe AP or sterile pancreatic necrosis. Material from infected pancreatic necrosis should be sampled by CT guided fine needle aspiration or minimally invasive drainage for microscopy and culture to guide treatment. Contrary to historical practice, enteral feeding is indicated immediately in AP without nausea or abdominal pain and may help to reduce infectious complications. Evidence suggests a low fat solid diet is as safe as a clear liquid diet and nasogastric and nasojejunal feeding offer similar efficacy. Cholecystectomy should be performed prior to discharge in cases of mild gallstone pancreatitis to prevent recurrence but should be delayed until fluid collection stabilises in necrotising biliary AP. Surgery is not required in cases of asymptomatic pancreatic pseudocysts or necrosis. In stable patients with infected necrosis drainage should be delayed by four weeks to allow necrosis liquefaction and walling-off.
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